Depletion of autoimmune CD20+ B cells was observed to be an insufficient treatment for SSc, and plasmablasts, which are responsible for producing autoantibodies, cannot be targeted via CD20, but can be targeted by CD19 [69]. This evidence concerns the gene CD19 and systemic sclerosis.